Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

GLP-1 receptor agonists have previously been evaluated as treatments for type 2 diabetes or obesity, and other work has also suggested that these drugs are neuroprotective in mouse models of PD. To investigate whether these findings extended into humans, the authors conducted a phase 2 clinical trial of 156 patients with PD from 21 clinics across France, with the primary goal of seeing whether lixisenatide could affect patients’ scores on part III of a survey called the MDS-UPDRS, which measures PD-associated motor symptoms.

GLP-1受体激动剂先前已被评估为治疗2型糖尿病或肥胖症的药物，其他研究也表明这些药物在PD小鼠模型中具有神经保护作用。为了研究这些发现是否扩展到人类，作者对来自法国21家诊所的156名PD患者进行了2期临床试验，主要目的是观察利西那肽是否会影响患者在MDS-UPDRS调查的第三部分的评分，该调查测量PD相关的运动症状。

All patients were in the early stages of disease onset and had only been diagnosed with PD within three years of the trial. Patients were evenly split into two groups who received a daily injection of either a placebo or 20 µg of lixisenatide for 12 months, alongside their current medication regime (for example, levodopa).Participants were brought into the clinic at 1–3-month intervals after the start of the trial, so that the authors could monitor their health.

所有患者均处于疾病发作的早期阶段，仅在试验的三年内被诊断出患有PD。患者被平均分为两组，每天注射安慰剂或20µg利西那肽，持续12个月，同时服用目前的药物（例如左旋多巴）。试验开始后，参与者每隔1-3个月被带到诊所，以便作者可以监测他们的健康状况。

In part, this meant the authors could watch out for the development of adverse side effects and adjust the patients’ treatment regimens. As described by the study’s corresponding author, Olivier Rascol, “we had about 40% of our patients [28/75] receiving the drug [lixisenatide] who complained of nausea, which was expected.

在某种程度上，这意味着作者可以注意不良副作用的发展，并调整患者的治疗方案。正如该研究的通讯作者Olivier Rascol所描述的那样，“我们大约有40%的患者（28/75）接受了药物[利西那肽]的治疗，他们抱怨恶心，这是意料之中的。

And we anticipated that some of the patients would have this kind of problem; rather than dropping out for side effects, we allowed them to down-titrate to 10 µg a day, half the dose.” Likewise, levodopa dosing was adjusted on a case-by-case basis, although Rascol highlights that this did not differ between the placebo and lixisenatide arms (~4.4 mg difference in levodopa dosing by the end of the study)..

我们预计一些患者会出现这种问题；我们不允许他们因副作用而退出，而是允许他们每天将滴定量降至10µg，即剂量的一半。”同样，左旋多巴的剂量也根据具体情况进行了调整，尽管Rascol强调安慰剂组和利西那肽组之间没有差异（到研究结束时，左旋多巴的剂量差异约为4.4 mg）。。

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Access Nature and 54 other Nature Portfolio journalsGet Nature+, our best-value online-access subscription24,99 € / 30 dayscancel any timeLearn moreSubscribe to this journalReceive 12 digital issues and online access to articles111,21 € per yearonly 9,27 € per issueLearn moreBuy this articlePurchase on Springer LinkInstant access to full article PDFBuy nowPrices may be subject to local taxes which are calculated during checkout.

Access Nature和54本其他Nature Portfolio journalsGet Nature+，我们最有价值的在线订阅24,99欧元/30天浏览所有时间获取更多订阅本期刊每年接收12期数字期刊和在线访问文章111,21欧元每期仅9,27欧元学习更多购买本文在Springer Links上购买即时访问完整文章PDFBuy Now价格可能需要缴纳结帐期间计算的当地税费。

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

Author informationAuthors and AffiliationsNature Aging https://www.nature.com/nataging/George Andrew S. InglisAuthorsGeorge Andrew S. InglisView author publicationsYou can also search for this author in

作者信息作者和附属机构年龄https://www.nature.com/nataging/GeorgeAndrew S.InglisAuthorsGeorge Andrew S.InglisView作者出版物您也可以在

PubMed Google ScholarCorresponding authorCorrespondence to

PubMed谷歌学者通讯社

George Andrew S. Inglis.Rights and permissionsReprints and permissionsAbout this articleCite this articleInglis, G.A.S. Slowing early Parkinson’s disease.

乔治·安德鲁·英格利斯。权利和许可打印和许可本文引用这篇文章，G.A.S.减缓早期帕金森病。

Nat Aging (2024). https://doi.org/10.1038/s43587-024-00660-wDownload citationPublished: 17 June 2024DOI: https://doi.org/10.1038/s43587-024-00660-wShare this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

Nat Aging（2024）。https://doi.org/10.1038/s43587-024-00660-wDownload引文发布日期：2024年6月17日OI：https://doi.org/10.1038/s43587-024-00660-wShare本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供